Colchicine benefits in treatment of type 2 autoimmune pancreatitis: Study

Following an endoscopic ultrasound-guided fine-needle biopsy to confirm their diagnosis, both patients were started on oral prednisone and had their prednisone dosage tapered over the course of 6 months.

The authors found the following:

• No genetic mutations (CTRC, CFTR, PRSS1, or SPINK1) were found in either patient.
• The prednisone therapy alleviated pancreatic gland swelling in the 19-year-old patient, and the 25-year-old patient experienced serologic remission, both after a month of treatment.
• Five months later, the 19-year-old patient started azathioprine and was also treated with subcutaneous methotrexate and prednisone, tapered over 4 months, each time following increases in his amylase and lipase levels. In June 2019, imaging showed "diffuse enlargement" of the pancreas, and the patient refused glucocorticoids. His methotrexate was tapered and withdrawn when he started oral colchicine.
• The 25-year-old patient experienced a recurrence of abdominal pain in June 2020, as well as increases in amylase and lipase levels and enlargement of the pancreas on imaging.
• After starting oral colchicine, serologic and radiographic findings normalized within 2 weeks for the 19-year-old patient and 20 days later for the 25-year-old patient. As of August 2021, neither patient experienced additional flares.

Thus, the researchers concluded that formal clinical studies are needed to confirm these "preliminary findings," but concluded that based on these results, colchicine could be a promising treatment for type 2 Autoimmune Pancreatitis.

Reference:

Treating Type 2 Autoimmune Pancreatitis With Colchicine: A Case Series by Chiabrando F et. al published in the Annals of Internal Medicine.

https://doi.org/10.7326/L21-0281